Advertisement

Autoimmune Thyroid Disease

  • Jessica R. Smith
  • Stephen A. Huang
Chapter

Abstract

Autoimmune thyroid disease affects approximately 2% of the female population and 0.2% of the male population. Its overall prevalence peaks in adulthood, but it is also the most common etiology of acquired thyroid dysfunction in pediatrics. This chapter presents a summary of autoimmune thyroid disease, discussing chronic autoimmune thyroiditis and Graves’ disease, with an emphasis on their clinical management. Normal levels of thyroid hormone are critical to neurodevelopment and growth, and by maintaining an appropriate index of suspicion, the clinician can often recognize thyroid dysfunction in its early stages.

Keywords

Thyroid Hypothyroidism Hyperthyroidism Autoimmune Hashimoto’s disease Graves’ disease Thyroiditis 

Notes

Acknowledgments

We are indebted to Dr. Reed Larsen, Chief of the Brigham and Women’s Hospital Thyroid Section in Boston, for helpful comments and assistance in the review of this chapter.

References

  1. 1.
    Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin N Am. 2001;30:315–37. viii.CrossRefGoogle Scholar
  2. 2.
    Hunter I, Greene SA, MacDonald TM, Morris AD. Prevalence and aetiology of hypothyroidism in the young. Arch Dis Child. 2000;83:207–10.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM. Special features of Graves’ disease in early childhood. Thyroid. 1999;9:871–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Lafranchi S. Thyroiditis and acquired hypothyroidism. Pediatr Ann. 1992;21(29):32–9.Google Scholar
  5. 5.
    Foley TP Jr, Abbassi V, Copeland KC, Draznin MB. Brief report: hypothyroidism caused by chronic autoimmune thyroiditis in very young infants. N Engl J Med. 1994;330:466–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Ostergaard GZ, Jacobsen BB. Atrophic, autoimmune thyroiditis in infancy. A case report. Horm Res. 1989;31:190–2.CrossRefPubMedGoogle Scholar
  7. 7.
    Davies TF, Amino N. A new classification for human autoimmune thyroid disease. Thyroid. 1993;3:331–3.CrossRefPubMedGoogle Scholar
  8. 8.
    Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335:99–107.CrossRefPubMedGoogle Scholar
  9. 9.
    Takasu N, Yamada T, Takasu M, et al. Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med. 1992;326:513–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Matsuura N, Konishi J, Yuri K, et al. Comparison of atrophic and goitrous auto-immune thyroiditis in children: clinical, laboratory and TSH-receptor antibody studies. Eur J Pediatr. 1990;149:529–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Feingold SB, Smith J, Houtz J, Popovsky E, Brown RS. Prevalence and functional significance of thyrotropin receptor blocking antibodies in children and adolescents with chronic lymphocytic thyroiditis. J Clin Endocrinol Metab. 2009;94:4742–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Foley TP. Disorders of the thyroid in children. In: Sperling MA, editor. Pediatric endocrinology. Philadelphia: Saunders Company; 1996. p. 171–94.Google Scholar
  13. 13.
    Chiesa A, Gruneiro de Papendieck L, Keselman A, Heinrich JJ, Bergada C. Final height in long-term primary hypothyroid children. J Pediatr Endocrinol Metab. 1998;11:51–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Boersma B, Otten BJ, Stoelinga GB, Wit JM. Catch-up growth after prolonged hypothyroidism. Eur J Pediatr. 1996;155:362–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Jannini EA, Ulisse S, D’Armiento M. Macroorchidism in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995;80:2543–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Anasti JN, Flack MR, Froehlich J, Nelson LM, Nisula BC. A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995;80:276–9.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. J Clin Invest. 1984;73:570–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23:38–89.CrossRefPubMedGoogle Scholar
  19. 19.
    Nordyke RA, Gilbert FI Jr, Miyamoto LA, Fleury KA. The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto’s thyroiditis. Arch Intern Med. 1993;153:862–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Foley TP Jr. Mediators of thyroid diseases in children. J Pediatr. 1998;132:569–70.CrossRefPubMedGoogle Scholar
  21. 21.
    Gereben B, Zavacki AM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29:898–938.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, et al. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014;370(14):1327–34.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J. 2014;3(2):76–94.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119:492–502.CrossRefPubMedGoogle Scholar
  25. 25.
    Salerno M, Capalbo D, Cerbone M, De Luca F. Subclinical hypothyroidism in childhood - current knowledge and open issues. Nat Rev Endocrinol. 2016;12(12):734–46.CrossRefPubMedGoogle Scholar
  26. 26.
    Radetti G, Gottardi E, Bona G, Corrias A, Salardi S, Loche S. The natural history of euthyroid Hashimoto’s thyroiditis in children. J Pediatr. 2006;149:827–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–751.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Van Dop C, Conte FA, Koch TK, Clark SJ, Wilson-Davis SL, Grumbach MM. Pseudotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism. N Engl J Med. 1983;308:1076–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Slyper AH, Swenerton P. Experience with low-dose replacement therapy in the initial management of severe pediatric acquired primary hypothyroidism. J Pediatr Endocrinol Metab. 1998;11:543–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Sklar CA, Qazi R, David R. Juvenile autoimmune thyroiditis. Hormonal status at presentation and after long-term follow-up. Am J Dis Child. 1986;140:877–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Maenpaa J, Raatikka M, Rasanen J, Taskinen E, Wager O. Natural course of juvenile autoimmune thyroiditis. J Pediatr. 1985;107:898–904.CrossRefPubMedGoogle Scholar
  32. 32.
    Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004;351:241–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549–55.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081–125.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Weetman AP. Graves’ disease. N Engl J Med. 2000;343:1236–48.CrossRefPubMedGoogle Scholar
  36. 36.
    Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358:2594–605.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lavard L, Ranlov I, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile thyrotoxicosis in Denmark, 1982–1988. A nationwide study. Eur J Endocrinol. 1994;130:565–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol. 2010;72:358–63.CrossRefGoogle Scholar
  39. 39.
    Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin N Am. 1998;27:109–26.CrossRefGoogle Scholar
  40. 40.
    Gruters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 5):S172–4.PubMedGoogle Scholar
  41. 41.
    Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18:333–46.CrossRefPubMedGoogle Scholar
  42. 42.
    Buckler JM, Willgerodt H, Keller E. Growth in thyrotoxicosis. Arch Dis Child. 1986;61:464–71.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefPubMedGoogle Scholar
  44. 44.
    Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, König J, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study. J Clin Endocrinol Metab. 2014;99(5):1648–55.CrossRefPubMedGoogle Scholar
  45. 45.
    Ly S, Frates MC, Benson CB, Peters HE, Grant FD, Drubach LA, et al. Features and outcome of autonomous thyroid nodules in children: 31 consecutive patients seen at a single center. J Clin Endocrinol Metab. 2016;101(10):3856–62.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.CrossRefPubMedGoogle Scholar
  47. 47.
    Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131.CrossRefPubMedGoogle Scholar
  48. 48.
    Utiger RD. Subclinical hyperthyroidism–just a low serum thyrotropin concentration, or something more? N Engl J Med. 1994;331:1302–3.CrossRefPubMedGoogle Scholar
  49. 49.
    Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905–17.CrossRefPubMedGoogle Scholar
  50. 50.
    Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94:1881–2.CrossRefPubMedGoogle Scholar
  51. 51.
    Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360:1574–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991;324:947–53.CrossRefPubMedGoogle Scholar
  53. 53.
    McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996;334:220–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Lucas A, Salinas I, Rius F, et al. Medical therapy of Graves’ disease: does thyroxine prevent recurrence of hyperthyroidism? J Clin Endocrinol Metab. 1997;82:2410–3.PubMedGoogle Scholar
  55. 55.
    Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983;98:26–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767–76.PubMedGoogle Scholar
  57. 57.
    Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000;85:3678–82.CrossRefPubMedGoogle Scholar
  58. 58.
    Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93:3817–26.CrossRefPubMedGoogle Scholar
  59. 59.
    Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997;7:755–60.CrossRefPubMedGoogle Scholar
  60. 60.
    Raza J, Hindmarsh PC, Brook CG. Thyrotoxicosis in children: thirty years’ experience. Acta Paediatr. 1999;88:937–41.CrossRefPubMedGoogle Scholar
  61. 61.
    Léger J, Kaguelidou F, Alberti C, Carel JC. Graves' disease in children. Best Pract Res Clin Endocrinol Metab. 2014;28(2):233–43.CrossRefPubMedGoogle Scholar
  62. 62.
    Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.CrossRefPubMedGoogle Scholar
  63. 63.
    Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab. 2007;92:801–3.CrossRefPubMedGoogle Scholar
  64. 64.
    Bauer AJ. Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted? J Clin Endocrinol Metab. 2011;96(3):580–8.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Ward L, Huot C, Lambert R, Deal C, Collu R, Van Vliet G. Outcome of pediatric Graves’ disease after treatment with antithyroid medication and radioiodine. Clin Invest Med. 1999;22:132–9.PubMedGoogle Scholar
  66. 66.
    Moll GW Jr, Patel BR. Pediatric Graves’ disease: therapeutic options and experience with radioiodine at the University of Mississippi Medical Center. South Med J. 1997;90:1017–22.CrossRefPubMedGoogle Scholar
  67. 67.
    Clark JD, Gelfand MJ, Elgazzar AH. Iodine-131 therapy of hyperthyroidism in pediatric patients. J Nucl Med. 1995;36:442–5.PubMedGoogle Scholar
  68. 68.
    Foley TP Jr, Charron M. Radioiodine treatment of juvenile Graves disease. Exp Clin Endocrinol Diabetes. 1997;105(Suppl 4):61–5.PubMedGoogle Scholar
  69. 69.
    Cheetham TD, Wraight P, Hughes IA, Barnes ND. Radioiodine treatment of Graves’ disease in young people. Horm Res. 1998;49:258–62.PubMedGoogle Scholar
  70. 70.
    Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89:4229–33.CrossRefPubMedGoogle Scholar
  71. 71.
    Refetoff S, Harrison J, Karanfilski BT, Kaplan EL, De Groot LJ, Bekerman C. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. N Engl J Med. 1975;292:171–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Baverstock K, Egloff B, Pinchera A, Ruchti C, Williams D. Thyroid cancer after Chernobyl. Nature. 1992;359:21–2.CrossRefPubMedGoogle Scholar
  73. 73.
    Nikiforov Y, Gnepp DR, Fagin JA. Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab. 1996;81:9–14.PubMedGoogle Scholar
  74. 74.
    LaFranchi SH, Hanna CE. Graves’ disease in the neonatal period and childhood. In: Braverman LE, Utiger RD, editors. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 9th ed. New York: Lippincott Williams & Wilkins; 2005. p. 1049–59.Google Scholar
  75. 75.
    Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Soreide JA, van Heerden JA, Lo CY, Grant CS, Zimmerman D, Ilstrup DM. Surgical treatment of Graves’ disease in patients younger than 18 years. World J Surg. 1996;20:794–9. discussion 9–800.CrossRefPubMedGoogle Scholar
  77. 77.
    Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–30.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas DC, Udelsman R, et al. Pediatric endocrine surgery: who is operating on our children? Surgery. 2008;144(6):869–77; discussion 77.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Waldhausen JH. Controversies related to the medical and surgical management of hyperthyroidism in children. Semin Pediatr Surg. 1997;6:121–7.PubMedGoogle Scholar
  80. 80.
    Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87:1073–7.PubMedGoogle Scholar
  81. 81.
    Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2007;92:S1–47.CrossRefPubMedGoogle Scholar
  82. 82.
    Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab. 2007;3:470–8.CrossRefPubMedGoogle Scholar
  83. 83.
    McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992;2:155–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves’ disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab. 1983;57:1036–40.CrossRefPubMedGoogle Scholar
  85. 85.
    Hashimoto H, Maruyama H, Koshida R, Okuda N, Sato T. Central hypothyroidism resulting from pituitary suppression and peripheral thyrotoxicosis in a premature infant born to a mother with Graves disease. J Pediatr. 1995;127:809–11.CrossRefPubMedGoogle Scholar
  86. 86.
    Mandel SH, Hanna CE, LaFranchi SH. Diminished thyroid-stimulating hormone secretion associated with neonatal thyrotoxicosis. J Pediatr. 1986;109:662–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Thyroid Program, Medicine/EndocrinologyBoston Children’s HospitalBostonUSA
  2. 2.Pediatrics, Medicine/Endocrinology DepartmentBoston Children’s HospitalBostonUSA

Personalised recommendations